Latest Health News

Page 8 of 271
Adheris Health delivered a stronger first quarter on revenue, margins and its CY27 sales pipeline, but ended September with US$3.5 million in cash after a US$3.1 million operating outflow. The company also disclosed the impending loss of a major pharmacy partner and a US$2.3 million-plus legal claim.
Ada Torres
Ada Torres
28 Oct 2026
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
Singular Health has moved closer to a proposed A$3.5 million Florida Medicaid imaging repository while deploying 1,000 physician licences through its largest customer network. The September quarter also exposed the execution risks ahead, with the Florida MOU still subject to definitive agreements and the PNS contract due for renewal by year-end.
Victor Sage
Victor Sage
27 Oct 2026
NRW Holdings delivered record FY26 revenue and earnings after folding Fredon into a new EMIT division, while debt-funded expansion lifted leverage. The company enters FY27 with A$7.5 billion of secured work, a larger banking facility and a sharper test of whether diversification can keep converting into cash.
Victor Sage
Victor Sage
27 Oct 2026
Lumos Diagnostics has expanded FebriDx deployment to 265 US healthcare sites across 29 states, while product revenue rose 224% in the first quarter. The commercial gains came alongside a US$4.7 million operating cash outflow, slower-than-planned paediatric study enrolment and a Hologic development timeline pushed to around June 2028.
Ada Torres
Ada Torres
27 Oct 2026
Resonance Health has secured an oversubscribed $6.0 million placement to fund MRI endpoint expansion, new TrialsWest sites and development of its non-invasive liver fibrosis device. The raise lifts pro forma net cash to $7.9 million, but the most consequential project remains an investigational technology backed by a small preliminary dataset.
Victor Sage
Victor Sage
27 Oct 2026
Locksley Resources is redirecting its exploration effort towards a district-scale copper-gold strategy in New South Wales, backed by A$13.383 million in cash. The company has also abandoned further investment in its Rice University antimony technology after concluding the commercial case was too uncertain.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Rhythm Biosciences has widened access to its ColoSTAT blood test, lifted quarterly revenue 64% and advanced reimbursement and NHS evaluation work. The progress sits alongside A$1.803 million in cash and an estimated 1.22 quarters of funding at the current operating burn.
Ada Torres
Ada Torres
27 Oct 2026
Eve Health Group (ASX:EVE) says it knows of no undisclosed information that would explain a sharp fall and surge in trading volume. The company suggested selling by a formerly associated shareholder may have contributed, without identifying the seller or quantifying the disposal.
Victor Sage
Victor Sage
26 Oct 2026
Island Pharmaceuticals has secured approvals to use Galidesivir in Uganda’s Bundibugyo Ebola outbreak while advancing two complementary Marburg studies and expanding manufacturing. The progress comes with a sharper funding question: cash fell to A$7.83 million after quarterly operating outflows of A$4.93 million, leaving an estimated 1.6 quarters of funding.
Victor Sage
Victor Sage
26 Oct 2026
Mach7 Technologies has delivered its first positive first-quarter operating cash flow, while ARR rose 8.5% in constant currency to A$23.5 million. The next test is whether increased product investment and the Flamingo rollout can translate into contracted sales.
Victor Sage
Victor Sage
26 Oct 2026

Browse the archive

Full archive